3.3 Pharmacogenetic variants and their clinical relevance for potential future medication
The frequencies of patients with a given number of identified PGx variants of different PHARMGKB classifications and according recommendations to adjust potential future pharmacotherapy are presented in Figure 3 and Table 4 . The 16-gene panel identified at least one “actionable”, “recommended“ or ”required” variant in 100% of the tested patients, and in 74.1% we found 2 or more concomitant “actionable” variants. The prevalence of the highly relevant “recommended” and “required” variants was lower. Still, 73.3% had one, and another 6.7% even two “recommended” variants, 38.5% one “required” variant, and 86.7% of all patients had at least one “recommended” or “required” variant.
As shown in Table 4 , the median number of alerts regarding clinically relevant PGx variants for potential future medication was 5 according to SONOGEN XP. Our reports provided a listing of those recommendations as an attachment, but the actual personalized expert assessments highlighted only those with the highest clinical relevance, hence the median number of recommendations in our personalized clinical reports was only 3 and therefore lower.